Introduction
Drug disposition is influenced by the combined action of drug transporters and metabolizing enzymes in organs such as the intestine, liver and kidney (Giacomini et al., 2010) . Drug-drug interactions (DDIs) can be complex, involving both uptake and efflux transporters as well as metabolizing enzymes including Cytochrome P450s (CYPs) (Elsby et al., 2012) . ATP-binding cassette (ABC) efflux transporters such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multi-drug resistance associated protein 2 (MRP2) are expressed in several organs with barrier function (e.g. the intestines, the blood-brain barrier, and the placenta), but are also expressed in the human liver, in the apical membrane facing the bile canaliculae (Klaassen and Aleksunes, 2010) . In the liver these transporters have an important role in excreting drugs and metabolites from the hepatocyte into the bile (Giacomini et al., 2010) . Liver P-gp has a central role in the elimination and pharmacokinetics of many drugs and is often working in concert with CYP3A4 as exemplified by erythromycin metabolism, while BCRP is central to e.g. rosuvastatin biliary efflux (Kurnik et al., 2006; Kitamura et al., 2008) There is a significant overlap in tissue localization and substrate selectivity between CYP3A4 and P-gp (Zhang and Benet, 2001 ).
To investigate whether the disposition of a compound is influenced by ABC efflux transporters, model inhibitors of individual transporters are frequently employed (recommendations have been published by both the US Food and Drug Administration and the European Medicines Agency (US FDA, 2006; , EMA, 2012 ). Many transporter studies are performed in cell lines such as Caco-2, MDCK or HEK cells that do not express significant levels of CYP enzymes. To obtain reliable estimates of efflux transporter contribution to drug disposition in more complex systems such as hepatocytes, selective inhibitors not affecting other involved transporters or enzymes are needed. However, data on the CYP and uptake
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This article has not been copyedited and formatted. The final version may differ from this version. Many ABC efflux transporter inhibitors are not selective but interact with other members of the super family. MK-571 was considered a selective inhibitor of the multidrug resistance associated protein family (MRP) but is now described to be almost as potent an inhibitor of the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) (Matsson et al., 2009) . Elacridar (formerly known as GF120918) was originally described to be P-gp selective but is today also recognized as a potent BCRP inhibitor (Matsson et al., 2009 ).
Additionally, several ABC efflux transporter inhibitors are known to also inhibit uptake transporters and CYP drug metabolizing enzymes (Treiber et al., 2007 , Parkinson, 2001 Zhang and Benet, 1995) . Cyclosporine A has often been used as a P-gp inhibitor but is also a potent inhibitor of CYP3A4 as well as organic anion transporting polypeptide (OATP) uptake transporters (Gertz et al., 2013) .
The methods routinely used to investigate hepatic DDIs include recombinant CYP enzymes, liver microsomes and isolated hepatocytes (Giacomini et al., 2010; Soars et al., 2009) . Only the last of these include the step of distribution across a cellular membrane and the influence of drug transporters. It is now well established that active transport processes may influence the intracellular concentration of a compound (Giacomini et al., 2010; Klaassen and Aleksunes, 2010) . The intracellular concentration of a compound can affect its potential to inhibit enzymes such as CYPs and it is therefore preferable to study CYP inhibition both in microsomes and isolated hepatocytes (Brown et al., 2007 (Brown et al., , 2010 .
This article has not been copyedited and formatted. The final version may differ from this version. The lack of information on the CYP inhibitory potential of efflux transporter inhibitors is an obstacle to experimental design when studying DDIs. We therefore investigated the CYP inhibition potential of several inhibitors, focusing on P-gp, MRP and BCRP inhibitors recommended for in vitro use by the US Food and Drug Administration (US FDA, 2006; Ozawa et al., 2004) . Some of these inhibitors are also suitable for in vivo studies (US FDA, 2012) Their CYP inhibitory effects where tested in human recombinant CYPs (isoforms 3A4, 2D6, 1A2, 2C9, and 2C19), human liver microsomes, and isolated cryopreserved human hepatocytes using several CYPselective probe substrates and the often used P-gp probe loperamide (Kalvass et al., 2013) .
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Material and methods

Reagents
Human recombinant enzymes were obtained from BD Gentest (BD Biosciences, San José, CA, USA) (CYP2D6) or were prepared in-house (CYP3A4, CYP2C9, CYP2A1, and CYP2C19 (Masimirembwa et al., 1999) ). Human liver microsomes were prepared in-house from a local bio-bank and a pool from seven individuals of mixed gender was used. Cryopreserved human hepatocytes (6-donor pool, mixed gender and lot OZL, SQI, REL, and AGR) were purchased from Celsis In Vitro Technologies (Baltimore, MD, USA). Probe substrates and inhibitors were all purchased from Sigma-Aldrich (St. Louis, MO, USA) except nelfinavir, ritonavir, and saquinavir, which were obtained from Toronto Research Chemicals (Toronto, ON, Canada). Cofactor NADPH, dimethyl-sulfoxide (DMSO), and Krebs-Henseleit buffer (KHL) were from Sigma-Aldrich.
Screening of CYP inhibitory effect
The CYP inhibitory effects of commonly used P-gp, MRP, and BCRP inhibitors (cyclosporin A, elacridar (GF120918), ketoconazole, nelfinavir, quinidine, reserpine, ritonavir, saquinavir, tacrolimus, verapamil, MK-571, probenicid, Fumitremorgin C (FTC) , and gefitinib) were determined using recombinant human enzymes in an Enzymatic activity for the five CYPS in the pools of microsomes and cryopreserved hepatocytes was determined as published previously using a cocktail of selective substrates (Floby et al., 2009; Sohlenius-Sternbeck et al., 2010) . CYP activities were determined to be close to long-time lab averages.
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Uptake measurements in hepatocytes
To test whether the P-gp inhibitors are substrates of hepatic uptake transporters, uptake measurements in suspended cryopreserved human hepatocytes were performed using the media loss technique described by Soars et al. (2007) . Briefly, hepatocytes (10 6 / ml) were incubated with test compound at a concentration of 1 μ M with the addition of 0.1% DMSO. At intervals ranging from 0 and 15 seconds up to 90 minutes aliquots were removed to a glass tube loaded into a bench top centrifuge and hepatocytes were pelleted by centrifugation. A sample of the buffer supernatant was removed and mixed with two volumes of an ice cold stop solution of acetonitrile (ACN) with 200 nM warfarin (internal standard) and processed as described above.
To study metabolism of the compound in the incubations aliquots of cells and media were removed and lysed without prior centrifugation. Intrinsic clearances, CL int, uptake and CL int, metabolism , were calculated as described (Soars et al., 2007) DMD #54932
where V R is the ratio between the cell volume and the incubation volume (0.005 at a cell concentration of 10 6 cells/ml).
The fraction unbound in the microsome incubations was predicted according to Hallifax and Houston (2006) :
where P is the microsomal protein concentration (0.5 mg/ml). In both equations 1 and 2 logP is used for bases and logD pH 7.4 for other ion classes. LogD and logP were calculated using a commercial package from Advanced Chemistry Development (Toronto, Canada).
Fraction unbound in microsome and hepatocyte incubations was also determined experimentally using the method published by Mateus et al., (2013) . Briefly, suspensions of human liver microsomes (0.5 µg/ml) and human cryopreserved hepatocytes (10 6 hepatocytes/ml) were homogenized by sonication. Each of the
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This article has not been copyedited and formatted. The final version may differ from this version. Table 2 were added to the homogenates at the highest and lowest concentration used. Samples were dialyzed against KHL in a Rapid Equilibrium Dialysis device (Thermo Fischer Scientific Inc., Rockford, IL, USA) at 37°C for 4 h. All compounds were stable during the incubation. After dialysis samples were analyzed by LC-MS/MS and the fu was calculated. Table 1 ). Quantification of each compound was achieved by comparison of the analyte/internal standard peak area ratios. A standard curve was included for each compound analysed spanning a concentration range from twice the initial experimental concentration to below the limit of quantification. Standard curves were not available for metabolites. For midazolam, 1´-hydroxylation was used as the probe reaction to monitor metabolism; for loperamide, N-desmethyl-loperamide; and for quinidine, hydroxy-quinidine was used. Data are presented as means ± SD.
LC-MS/MS analysis
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Statistical analysis
Data were analyzed using Graphpad Prism 5 software. IC50 determinations were performed utilizing non-linear regression. Statistical significance was tested using the two-tailed Student's t-test. Probability values (P-values) are symbolized by: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, p-values of p < 0.05 were considered statistically significant.
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Results
Cytochrome P450 inhibition by ABC-transporter inhibitors
The calculated IC50 values for each inhibitor for each human recombinant CYP are listed in Table 2 (IC50 values in Table 2 are based on the total concentration of inhibitor). The inhibition seen was classified into three categories, potent, moderate or weak. Potent: CYP IC50 below published IC50 values for the relevant transporter;
Moderate: CYP IC50 from equal to tenfold higher than IC50 values reported for the ABC-transporter; Weak: CYP IC50 values more than tenfold higher than reported transporter IC50 values. As can be seen all P-gp inhibitors except elacridar, reserpine and verapamil were potent or moderate inhibitors of CYP3A4.
Ketoconazole was the most potent CYP3A4 inhibitor with 50-fold more potent CYP3A4 than P-gp inhibition. MRP and BCRP inhibitors were less potent towards CYP3A4. Of these only MK-571 showed moderate CYP3A4 inhibition. CYP2C19 was the second most affected CYP but inhibitors were generally less potent against this isoform. The P-gp inhibitors elacridar and reserpine and the MRP inhibitor probenicid were exceptions to this general trend and were more potent inhibitors of CYP2C19 than CYP3A4. Reserpine was an extremely potent CYP2C19 inhibitor. Quinidine and reserpine were particularly powerful inhibitors of CYP2D6, while ritonavir and saquinavir were moderate inhibitors. In contrast CYP1A2 and CYP2C9 were only inhibited moderately by a few of the ABC-transporter inhibitors (CYP1A2, nelfinavir; CYP2C9, ritonavir, saquinavir and MK-571).
No correlation between CYP3A4 IC50 values measured in this study and P-gp literature IC50 values was found (r 2 =0.36, p=0.073, data not shown). There was no correlation between P-gp and CYP2C19 IC50 values (r 2 = 0.003, p= 0.89).
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CYP inhibition in human microsomes and cryopreserved hepatocytes
The inhibitory effects on CYP-mediated metabolism of the probe substrates loperamide and midazolam by the 6 P-gp inhibitors listed in Table 3 were studied in human microsomes and cryopreserved hepatocytes. For most inhibitors the determined IC50 was either similar in microsomes and hepatocytes (cyclosporin A, tacrolimus) or higher in hepatocytes (elacridar, ketoconazole, reserpine) (Table 3) . Table 3 are based on the total concentration of inhibitor.
IC50 values in
Quinidine was an exception that for both probe substrates showed a statistically significant lowered IC50 values for midazolam (10-fold) and loperamide (20-fold) metabolism in hepatocytes compared to microsomes (Table 3 ).
Inhibition by the tested P-gp inhibitors in liver microsomes and hepatocytes was generally similar for both probe substrates used with the exception of reserpine, and to some extent quinidine, that both inhibited loperamide metabolism more strongly than midazolam metabolism (significantly different IC50 values depending on probe substrate, p < 0.01 and p < 0.001 for quinidine and reserpine, respectively, Table 3 ).
To test whether differences in binding in microsomes and hepatocytes could explain the differences in IC50 values obtained, fraction unbound in microsome and hepatocyte incubations was calculated using equations 1 and 2 for midazolam, loperamide, and the P-gp inhibitors listed in Table 3 . Fraction unbound was also determined experimentally. The predicted differences in binding between microsome and hepatocyte experiments amounted to less than 30% for all these compounds.
When measuring binding it was found that for most compounds the predicted binding was underestimated by a factor of 2 or more. However, measured fu inc was very similar in microsomes and hepatocytes for all compounds with the exception of elacridar that showed a more than 2-fold difference in binding between the two
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Hepatocyte uptake of ABC-transporter inhibitors
The uptake of two inhibitors, elacridar and quinidine, was measured by the media loss method in suspensions of cryopreserved human hepatocytes. Elacridar showed no significant uptake by the cells (data not shown) while quinidine was subject to rapid uptake and substantial cellular accumulation. As can be seen in Fig. 1 hepatocyte uptake of quinidine was rapid and extensive, while metabolism was slow.
Calculating intrinsic clearances for the two processes gave values of CL int, metabolism = 4.6 μ l/min/10 6 cells, and CL int, uptake = 130 μ l/min/10 6 cells (calculated according to Soars et al., 2007 , incorporating fu inc from Eqs 1 and 2).
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Discussion
When investigating potential drug-drug interactions in vitro or in vivo, selective inhibitors are needed that will affect the system investigated without unwanted effects on other components involved in the disposition of the drug. Many CYP inhibitors show substrate dependent effects and IC50 values should be interpreted with caution (Stresser et al., 2000) . Quinidine and ketoconazole IC50 values listed in Table 2 are similar to data reported in the literature (Khojasteh et al., 2011) . However, absolute
CYP IC50 values could vary dependent on substrates and experimental systems
used.
Most of the tested P-gp inhibitors showed potent or moderate CYP3A4 as well as moderate CYP2C19 inhibition. However, for three compounds (elacridar, reserpine, and verapamil) inhibition of P-gp was much more potent than the CYP3A4 inhibition.
These should be possible to use experimentally for efficient P-gp inhibition without In addition to CYP3A4 most of the P-gp inhibitors also exhibited CYP2C19 inhibition.
CYP2C9, CYP2D6 and CYP1A2 showed less inhibition by the P-gp inhibitors suggesting that CYP3A4 and CYP2C19 are the major enzymes to consider when
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This article has not been copyedited and formatted. The final version may differ from this version. designing P-gp inhibition experiments. A notable exception was the P-gp inhibitors reserpine and quinidine that potently inhibited CYP2D6.
It has been reported that P-gp and CYP3A4 show a large overlap in inhibitor and substrate recognition (Wacher et al., 1995; Kim et al., 1999; Wandel et al., 1999; Yasuda et al., 2002) . However, studies on overlap between P-gp and CYP3A4 could find no correlation between IC50 values for the two proteins (Wandel et al., 1999; Kim et al., 1999) . This latter finding was supported in this study where no correlation was seen between P-gp and CYP3A4 IC50 values. It was recently demonstrated that P-gp IC50 values shows very large intra-lab and intra-method variability which might obscure a correlation between CYP3A4 and P-gp inhibitor potencies (Bentz et al., 2013 ).
The tested MRP and BCRP inhibitors showed weak CYP inhibition. This is consistent showed small uptake in cryopreserved human hepatocytes in suspension possibly due to P-gp mediated efflux of the inhibitor. Many P-gp inhibitors, including elacridar, are also substrates of the transporter (Bankstahl et al., 2013; Morrissey et al., 2012; Ozawa et al., 2004) . We have recently shown that ABC efflux transporters, including P-gp, are present and active in human cryopreserved hepatocytes (Lundquist et al., unpublished) . For inhibitors that are efflux transporter substrates or display differences in binding between microsome and hepatocyte incubations the higher IC50 value measured in cryopreserved hepatocytes might be more indicative of their in vivo IC50.
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In contrast to other tested inhibitors quinidine showed much more potent CYP inhibition in hepatocytes than in human liver microsomes, regardless of the probe substrate used. This could be due to cellular accumulation of quinidine by active uptake and the compound was found to be rapidly taken up by human cryopreserved hepatocytes. Quinidine is known to be a substrate of several OATPS and OCTs (Morrissey et al., 2012; Ozawa et al., 2004) .
Uptake of an inhibitor in hepatocytes can have different consequences. Often it leads to no change in the inhibitor potency as the accumulation of compound intracellularily is masked by binding (Brown et al., 2007; Grime et al., 2008) . It has been shown by Brown and coworkers that CYP inhibition was amplified by active uptake in hepatocytes for low clearance compounds but not for more rapidly metabolized substances (Brown et al., 2010) . This fits well with the CL int, metabolism measured for quinidine in hepatocytes, 4.6 μ l/min/10 6 cells (in vivo human CL 4 ml/min/kg (Obach et al., 1997) ). It is therefore likely that the amplification of quinidine CYP inhibition by active uptake is even larger in vivo or in fresh hepatocytes since many uptake transporters, including OATPs and OCTs, are active but down regulated in human cryopreserved hepatocytes (Lundquist et al., unpublished) . Down regulation of OATPs in cryopreserved hepatocytes has also been demonstrated by Badolo et al. (2011) and Kimoto et al. (2012) .
Finally it is not sufficient to consider ABC-transporter and CYP inhibition when selecting an inhibitor for P-gp (or other ABC-transporters) inhibition experiments.
Cyclosporin A has IC50 values for human OATP1B1 and OATP1B3 in a clinically relevant range between 0.2 to 0.5 and 0.5 to 0.8 µM, respectively, below the IC50 for P-gp of 1.3 µM (Shitara et al., 2003; Ho et al., 2006; Treiber et al., 2007) . The uptake
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This article has not been copyedited and formatted. The final version may differ from this version. Metabolism and uptake of quinidine in human cryopreserved hepatocytes. The P-gp inhibitor quinidine exhibited slow metabolism but rapid uptake into hepatocytes.
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